Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Accu-Chek

Novartis to expand SMS for Life approach across Africa

Will broaden reach of mobile-based medicines management programme 

Roche - Basel

Roche’s Herceptin follow-up cleared in US

FDA approval for Kadcyla (formerly T-DM1) in breast cancer

Apple curates HCP iPhone and iPad apps

Sanofi bags first pharma place on new iTunes App Store collection lists

- PMLiVE

Novartis, Roche under scrutiny in Italy on Avastin/Lucentis collusion claims

Antitrust authorities in Italy open investigation into the pharma companies

- PMLiVE

OncoAssist becomes latest app to be classified as a medical device

Cancer iPhone and iPad app offers clinical decision support tools

Sanofi reception

FDA to review Sanofi’s lixisenatide for diabetes

Follows drug's European approval under brand name Lyxumia earlier this month

Roche - Basel

Roche licenses Chiasma’s acromegaly drug in $595m deal

Alternative to injection for hormonal disorder

- PMLiVE

FDA turns down Novo Nordisk’s Tresiba and Ryzodeg

Decision could delay the US launch of the diabetes drugs by two years or more

- PMLiVE

Sanofi backs SMS chemotherapy compliance programme

Prost8Care delivers timed text message encouragement to cancer patients

- PMLiVE

Sanofi receives EU approvals for diabetes and cancer drugs

Zaltrap and Lyxumia granted marketing authorisation by European Commission

- PMLiVE

NICE turns down diabetes and ovarian cancer drugs for NHS use

Disappointment for BMS/AZ’s Forxiga and Roche’s Avastin

Roche - Basel

Roche delivers solid sales gain in 2012

New cancer products, such as Perjeta and Zelboraf, help growth

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links